D
Cellectis S.A. CLLS
$2.62 -$0.02-0.76%
Recommendation
Sell
Prev Close
$2.55
Volume
18,967
Avg Vol (90D)
56,187
Market Cap
$182.92M
Dividend & Yield
--
52-Week Range
$0.9628 - $3.77
P/E (TTM)
--
EPS (TTM)
-$1.68
My Lists My Alerts
Report
Rating
Reward
E
Very Weak
Risk
D
Weak
Rating Factors
Growth Index
Fair
Efficiency Index
Very Weak
Solvency Index
Good
Total Return Index
Weak
Volatility Index
Weak
Dividend Index
--
Headlines
Cellectis Unveils Groundbreaking Gene-Editing Advances
4/22/2024 - TipRanks Financial Blog
Cellectis (NASDAQ:CLLS) Downgraded by StockNews.com
4/15/2024 - Ticker Report
Cellectis Unveils Gene Therapy Breakthrough
4/11/2024 - TipRanks Financial Blog
Cellectis publishes new research paper in Molecular Therapy
4/10/2024 - The Fly
Cellectis Publishes a Novel Intronic Gene Editing Approach For the Treatment of Inborn Metabolic Diseases by Edited HSPCs
4/10/2024 - Globe Newswire
Cellectis Unveils Breakthrough Gene-Editing Innovations
4/8/2024 - TipRanks Financial Blog
Cellectis Announces Two Poster Presentations on Novel TALEN Editing Process for Gene Correction and Gene Insertion in HSPCs at the ASGCT Annual Meeting
4/8/2024 - Globe Newswire
Cellectis (NASDAQ:CLLS) Shares Pass Above Fifty Day Moving Average of $2.74
3/31/2024 - Zolmax
Cellectis: Pushing A Different Kind Of CAR-T Up The Hill
1/22/2024 - SeekingAlpha
Cellectis draws down second tranche under EIB credit facility
1/16/2024 - Seeking Alpha - Healthcare
Cellectis announces the drawdown of the second tranche of 15 million under the credit facility agreement entered with the European Investment Bank (EIB)
1/16/2024 - Globe Newswire
Head to Head Review: Cellectis (NASDAQ:CLLS) & Curis (NASDAQ:CRIS)
1/16/2024 - Zolmax
Cellectis SA: A Hold Rating Amidst Strategic Partnerships and Pipeline Potential
1/13/2024 - TipRanks Financial Blog
Cellectis SA (CLLS, $3.09) entered Downtrend as Momentum indicator drops below 0 level on Jan 02, 2024
1/3/2024 - Tickeron - Stocks
Cellectis SA (CLLS, $3.07) Moving Average Convergence Divergence (MACD) Histogram turned negative on December 29, 2023
12/30/2023 - Tickeron - Stocks
Palatin Technologies, Cellectis among healthcare movers
12/29/2023 - Seeking Alpha - Healthcare
Cellectis Reports Results from Shareholders Meeting Held on December 22, 2023
12/22/2023 - Globe Newswire
Cellectis SA (CLLS, $3.37) RSI Indicator left the overbought zone on December 21, 2023
12/22/2023 - Tickeron - Technical Analysis
Cellectis SA (CLLS, $3.34) RSI Indicator left the overbought zone on December 19, 2023
12/20/2023 - Tickeron - Stocks
Cellectis SA (CLLS, $3.34) Moving Average Convergence Divergence (MACD) Histogram turned positive on December 19, 2023
12/20/2023 - Tickeron - Stocks
Cellectis SA (CLLS, $3.31) price may drop as it broke higher Bollinger Band on Dec 18, 2023
12/19/2023 - Tickeron - Stocks
Cellectis price target lowered to $10 from $12 at Citi
11/22/2023 - The Fly
Cellectis SA (CLLS, $3.05) RSI Indicator left the overbought zone on November 20, 2023
11/21/2023 - Tickeron - Technical Analysis
Cellectis (NASDAQ:CLLS) Now Covered by Analysts at StockNews.com
11/21/2023 - Zolmax
Income Statement
Total Revenue (TTM)
$24.53M
EBITDA (TTM)
-$62.96M
EBIT (TTM)
-$72.92M
Net Income (TTM)
-$85.02M
Balance Sheet
Total Assets (Q)
$209.70M
Total Debt (Q)
$83.53M
Total Liabilities (Q)
$133.58M
Book Value Per Share (Q)
$1.37
Cash Flow
Cash from Operations (TTM)
-$64.46M
Cash from Investing (TTM)
-$1.86M
Cash from Financing (TTM)
$41.29M
Net Change in Cash (TTM)
-$25.86M
Filings
Filing Date
Monday, November 6, 2023
Period Date
Saturday, September 30, 2023
Next Filing
(est)
Price History
Loading...
Beta
3.51
7-Day Total Return
-8.18%
30-Day Total Return
1.65%
60-Day Total Return
-16.84%
90-Day Total Return
-14.83%
Year to Date Total Return
-19.54%
1-Year Total Return
27.98%
2-Year Total Return
-35.00%
3-Year Total Return
-87.06%
5-Year Total Return
-88.01%
52-week Low
Oct 26, 2023 - $0.9628
52-week High
Dec 20, 2023 - $3.77
Valuation
Market Cap
$182.92M - Micro Cap
Enterprise Value
$199.21M
Price/Sales (TTM)
5.78
Price/Book (Q)
1.86
Dividends and Shares
Shares Outstanding
55.58M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.cellectis.com
Phone Number
33 1 81 69 16 00
Address
8, rue de la Croix Jarry
Paris, 75013
Country
France
Year Founded
1999
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer... more
NASDAQ 04/23/2024 10:14AM Eastern Quotes delayed
Weiss Ratings